Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis

NCT05916365 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.

NCT NCT05916365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05916365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
Almirall, S.A.
Phase
Phase 3
Overall status
Completed
Start date
May 23, 2023
Completion date
April 23, 2026
Enrollment
174 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis